Parkinson’s disease, the second most common type of progressive dementia after Alzheimer’s disease, affects nearly 1 million people in the U.S. and an estimated 10 million individuals worldwide.
Cybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder | Psychedelic Invest
TORONTO–(BUSINESS WIRE)–Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation
March 13, 2024